雾化吸入丙酸倍氯米松混悬液治疗儿童轻中度哮喘急性发作有效性及安全性研究  

Efficacy and safety of nebulized beclometasone dipropionate suspension in the treatment of mild to moderate childhood asthma exacerbations

作　　者：陈乐[1] 苏雯[1] 俞善昌[1] 李云珠[1] 邵洁[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院儿科,上海200025

出　　处：《中国实用儿科杂志》2015年第8期601-604,共4页Chinese Journal of Practical Pediatrics

摘　　要：目的观察雾化吸入丙酸倍氯米松(BDP)混悬液治疗儿童哮喘轻、中度急性发作的临床有效性和安全性。方法收集2014年9月至2015年2月在上海交通大学医学院附属瑞金医院儿科就诊的63例5岁以下哮喘轻、中度急性发作的患儿,随机分为BDP组和布地奈德(BUD)组,分别给予每日2次雾化吸入BDP混悬液(每次800μg)或BUD混悬液(每次1 mg),同时联合雾化特布他林溶液(每次2.5 mg)。评估两组患儿治疗前及治疗后30 min、60 min、1 d、3 d、5 d、7 d的临床症状、体征评分,比较两组患儿症状缓解情况及症状持续天数,观察不良事件发生情况。结果 BDP组患儿治疗后30 min、60 min的临床评分降至3.43±1.07(30 min),2.97±1.13(60 min),较治疗前的4.33±0.99明显下降(P<0.001);BUD组患儿治疗后30 min、60 min的临床评分也较治疗前显著下降(3.52±0.77 vs 3.10±0.70 vs 4.29±0.94,P<0.001),组间差异无统计学意义(P=0.702)。观察终点时,BDP组和BUD组分别有26例(86.7%)和28例(90.3%)患儿获得完全缓解,症状持续天数分别为(5.00±1.70)d(BDP组)和(5.42±1.25)d(BUD组),组间差异无统计学意义(P>0.05)。两组均无不良事件发生。结论雾化吸入BDP混悬液可有效缓解轻、中度哮喘急性发作患儿病情,有效性和安全性与布地奈德混悬液相当。Objective To observe the efficacy and safety of beclometasone dipropionate （BDP） suspension in the treatment of children with mild to moderate asthma episode. Methods Sixty-three children younger than 5 years old with mild to moderate exacerbation of asthma were obtained in the outpatient of Pediatrics in Ruijin Hospital affiliated to Shanghai Jiaotong University. The participants were randomly divided into two group：BDP group and BUD group,respectively receiving nebulized BDP （ 800 μg） or Budesonide （ BUD, 1 mg） suspension twice a day, with the addition of nebulized terbutaline sulfate aerosol liquid （2.5 mg）. Assess the clinical score before nebulization and 30,60 minutes, 1, 3,5 and 7 days after therapy. Compare the efficacy by demonstrating the changes of clinical scores and symptoms duration, and observe the prevalence of adverse events. Result In the BDP group, the clinical scores decreased from 4.33±0.99 before treatment to 3.43± 1.07 （30 min after nebulization ） and 2.97±1. 13 （60 min after nebulization ） respectively, the changes being significant （P 〈 0.001 ）. The similar results were also observed in BUD group, and the clinical scores decreased significantly from 4.29±0.94 to 3.52±0.77 and 3.10±0.70 （P 〈 0.001 ）. The changes between two groups were not statistically significant （P = 0.702）. At the end point of this trial, 26 （86.7%） cases in BDP group obtained the complete remission , while 28 cases （90.3%） had no symptoms in BUD group, and the complete remission rate between two groups was not statistically significant （P 〉 0.05 ）. The symptoms duration was 5.00± 1.70 days in BDP group and 5.42± 1.25 days in BUD group respectively, and the difference between two groups was not significant （P 〉 0.05 ）. No adverse events were reported in two groups. Conclusion The results of this research demonstrate that both nebulized BDP and BUD can relieve the mild to moderate acute asthma exacerbation in children, andthe curative effect and sate

关 键 词：哮喘 丙酸倍氯米松 布地奈德 雾化吸入 

分 类 号：R72[医药卫生—儿科]